Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
|Videos|August 18, 2022
Psilocybin: The Complicated Conversation
Author(s)John J. Miller, MD
The resistance against "magic mushrooms"—is it justified?
Advertisement
John J. Miller, MD, tries to untangle the controversies around psilocybin in this video and in his talk at the
Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times™; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Exeter Hospital, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.
Advertisement
Related to this article
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Scams: What Psychiatrists Need to Know
2
FDA Shelves Fast-Track Drug Review Initiative
3
Reviewing Roluperidone as Treatment for Negative Symptoms in Schizophrenia
4
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
5